<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee180398ef2">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">2001-05-08</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>11 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:GAO-01-705T</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-01-705T</identifier>
<identifier type="local">P0b002ee180398ef2</identifier>
<identifier type="former package identifier">f:d01705t</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-23</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-GAO-01-705T</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-GAO-01-705T</accessId>
 <reportNumber>GAO-01-705T</reportNumber>
 <subject>Children</subject>
 <subject>Drugs</subject>
 <subject>Pharmaceutical industry</subject>
 <subject>Pharmacological research</subject>
 <type>Testimony</type>
 <accountNo>A00964</accountNo>
 <law congress="97" isPrivate="false" number="414"></law>
 <law congress="98" isPrivate="false" number="417"></law>
</extension>
<titleInfo>
 <title>Pediatric Drug Research: Substantial Increase in Studies of Drugs for Children, But Some Challenges Remain</title>
</titleInfo>
<abstract>Children are subject to many of the same diseases as adults and
are often treated with the same drugs. However, only about 25	 
percent of drugs used today have been labeled for pediatric	 
patients. The lack of pediatric testing and labeling can place	 
children at risk of under- or overdosing, and the lack of	 
age-appropriate formulations, such as liquids or chewable	 
tablets, can result in improper administration of drugs. The	 
pediatric exclusivity provision of the Food and Drug		 
Administration Modernization Act of 1997 has been successful in  
encouraging drug sponsors to generate needed information about	 
how drugs work in children. A wide range of drugs are being	 
studied in many therapeutic areas. The infrastructure for	 
conducting pediatric trials has also been greatly strengthened,  
which should help to support continued progress. While a number  
of drug labels have been changed to incorporate findings from	 
research conducted under the pediatric exclusivity provision,	 
label changes typically occur long after the Food and Drug	 
Administration has granted the extension of market exclusivity.  
In addition, there continues to be little incentive to conduct	 
pediatric research on off-patent drugs.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-01-705T/html/GAOREPORTS-GAO-01-705T.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-01-705T/pdf/GAOREPORTS-GAO-01-705T.pdf</url>
</location>
<identifier type="preferred citation">GAO-01-705T</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-01-705T</url>
</location>
<note>Testimony</note>
<extension>
 <searchTitle>GAO-01-705T; Pediatric Drug Research: Substantial Increase in Studies of Drugs for Children, But Some Challenges Remain;
            </searchTitle>
</extension>
<subject>
 <topic>Children</topic>
 <topic>Drugs</topic>
 <topic>Pharmaceutical industry</topic>
 <topic>Pharmacological research</topic>
</subject>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 414 (97th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 97-414</identifier>
</relatedItem>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 417 (98th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 98-417</identifier>
</relatedItem>
</mods>